Themasap Khan
Co-Founder and Partner @ Luma Group
Silicon Valley, United States
Themasap Khan is a Series A investor at Luma Group in Silicon Valley focused on Health Care and Biotechnology. Themasap A. Khan is based out of New York, New York, and is the Co-Founder and Partner at Luma Group and Board of Director at Aeovian Pharmaceuticals. Themasap previously served as the Senior Advisor at Civilization Ventures. Themasap A. Khan attended New York University. Themasap A. Khan has received National Science Foundation GraduateFellowship award.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Themasap Khan invests in
Stages Themasap Khan invests in
Countries Themasap Khan invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (100%)
- Biotechnology 2 (100%)
- Biopharma 1 (50%)
- Pharmaceutical 1 (50%)
- Health Diagnostics 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Aeovian Pharmaceuticals develops and investigates targeted small molecule therapeutics aimed at restoring cellular metabolic quality control to address dysregulated growth and signaling linked to certain rare genetic and age-related conditions. The company’s pipeline centers on compounds that selectively modulate specific biological pathways,including inhibitors designed to influence disease processes associated with neurological dysfunction. Its lead development candidate is a central nervous system-penetrant selective inhibitor being evaluated in clinical trials for refractory seizures related to a genetic disorder, and additional compounds are in earlier stages of investigation for other disease areas. Aeovian Pharmaceuticals also maintains a portfolio of proprietary molecules that engage defined molecular targets to explore potential treatments beyond its program. | $55M / Series B / Dec 16, 2025 | ||
| Curve Biosciences is a biotechnology company focused on enhancing chronic disease care through precision medicine. With a team led by experts such as Nathan Hunkapiller, PhD, as Chief Scientific Officer, and Chuba Oyolu, PhD, as Chief Technology Officer, the company is at the forefront of research and development in the biotech field. CurveBiosciences aims to leverage scientific advancements to provide targeted solutions for chronic diseases, emphasizing the importance of precision in treatment approaches. The company operates within the biotechnology industry and is dedicated to improving patient outcomes through innovative research. | $40M / Series A / Oct 29, 2025 |
Co-Investors
About Luma Group
Luma Group is an investment firm focused on the intersection of technology-driven life sciences and healthcare companies.
Luma Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Themasap Khan
Co-Founder and Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Themasap Khan invest in?
Themasap Khan invests primarily in Health Care, Biotechnology and Biopharma startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Themasap Khan?
Public channels for Themasap Khan include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Themasap Khan last invest?
The most recent investment recorded for Themasap Khan closed in Dec 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
